These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22287731)

  • 21. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway.
    Arafa el-SA; Zhu Q; Barakat BM; Wani G; Zhao Q; El-Mahdy MA; Wani AA
    Cancer Res; 2009 Dec; 69(23):8910-7. PubMed ID: 19903849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells.
    Fujiwara M; Izuishi K; Sano T; Hossain MA; Kimura S; Masaki T; Suzuki Y
    J Exp Clin Cancer Res; 2008 Nov; 27(1):76. PubMed ID: 19032736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
    Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
    Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.
    Schlosshauer PW; Li W; Lin KT; Chan JL; Wang LH
    Gynecol Oncol; 2009 Sep; 114(3):516-22. PubMed ID: 19576622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
    Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia.
    Kayabasi C; Yelken BO; Asik A; Okcanoglu TB; Sogutlu F; Gasimli R; Susluer SY; Saydam G; Avci CB; Gunduz C
    Eur J Pharmacol; 2021 Nov; 910():174446. PubMed ID: 34461124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
    Shingu T; Yamada K; Hara N; Moritake K; Osago H; Terashima M; Uemura T; Yamasaki T; Tsuchiya M
    Cancer Res; 2003 Jul; 63(14):4044-7. PubMed ID: 12874004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway].
    Zhang XJ; Zhang L; Liu YP; Xu HM; Sun P; Song JG; Luo YH
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):181-6. PubMed ID: 23879997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wortmannin enhances cisplatin-induced apoptosis in human ovarian cancer cells in vitro.
    Zhao JX; Liu H; Lv J; Yang XJ
    Eur Rev Med Pharmacol Sci; 2014; 18(17):2428-34. PubMed ID: 25268086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.
    Correa RJ; Valdes YR; Peart TM; Fazio EN; Bertrand M; McGee J; Préfontaine M; Sugimoto A; DiMattia GE; Shepherd TG
    Carcinogenesis; 2014 Sep; 35(9):1951-61. PubMed ID: 24562574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
    Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells.
    Wang Y; Kuramitsu Y; Baron B; Kitagawa T; Tokuda K; Akada J; Maehara SI; Maehara Y; Nakamura K
    Int J Oncol; 2017 Feb; 50(2):606-612. PubMed ID: 28000865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LY294002 enhances inhibitory effect of gemcitabine on proliferation of human pancreatic carcinoma PANC-1 cells.
    Ke XY; Wang Y; Xie ZQ; Liu ZQ; Zhang CF; Zhao Q; Yang DL
    J Huazhong Univ Sci Technolog Med Sci; 2013 Feb; 33(1):57-62. PubMed ID: 23392708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
    Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
    Caumanns JJ; van Wijngaarden A; Kol A; Meersma GJ; Jalving M; Bernards R; van der Zee AGJ; Wisman GBA; de Jong S
    Cancer Lett; 2019 Oct; 461():102-111. PubMed ID: 31319139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The O-methylated isoflavone, formononetin, inhibits human ovarian cancer cell proliferation by sub G0/G1 cell phase arrest through PI3K/AKT and ERK1/2 inactivation.
    Park S; Bazer FW; Lim W; Song G
    J Cell Biochem; 2018 Sep; 119(9):7377-7387. PubMed ID: 29761845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel PI3K/Akt/mTOR signaling inhibitor, W922, prevents colorectal cancer growth via the regulation of autophagy.
    Wang J; Liang D; Zhang XP; He CF; Cao L; Zhang SQ; Xiao X; Li SJ; Cao YX
    Int J Oncol; 2021 Jan; 58(1):70-82. PubMed ID: 33367926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
    Santiskulvong C; Konecny GE; Fekete M; Chen KY; Karam A; Mulholland D; Eng C; Wu H; Song M; Dorigo O
    Clin Cancer Res; 2011 Apr; 17(8):2373-84. PubMed ID: 21372221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenoxodiol enhances the antitumor activity of gemcitabine in gallbladder cancer through suppressing Akt/mTOR pathway.
    Li Y; Huang X; Huang Z; Feng J
    Cell Biochem Biophys; 2014 Nov; 70(2):1337-42. PubMed ID: 24902539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.